NOVAVAX INC
Biological Products, (No Diagnostic Substances) · 21 FIRSTFIELD RD, GAITHERSBURG, MD
官方登記資料
0位追蹤者
1987成立於
關於 NOVAVAX INC
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.
Source: Wikipedia
產業Biological Products, (No Diagnostic Substances)
總部21 FIRSTFIELD RD, GAITHERSBURG, MD
成立時間1987
法律形式C Corporation
狀態營運中
專利18 項專利
VACCINE COMPOSITIONS HAVING IMPROVED STABILITY AND IMMUNOGENICITYJP2025128159A · 2025
VACCINE COMPOSITIONS HAVING IMPROVED STABILITY AND IMMUNOGENICITYJP2024038170A · 2024
關鍵數據
法律資訊
| 法定名稱 | NOVAVAX INC |
|---|---|
| 法律形式 | C Corporation |
| SEC CIK | 1000694在 SEC EDGAR 上查看 ↗ |
| EIN | 22-2816046 |
| 產業代碼(SIC) | 2836 |
| 登記地址 | 21 FIRSTFIELD RD, GAITHERSBURG, MD |
| 狀態 | 營運中 |
來源: SEC EDGAR · 更新於 2026年10月15日